There’s a specific reason “I tried HRT and my sex drive still didn’t come back” is one of the most common things women say about menopause treatment. It’s not that HRT failed. It’s that most prescriptions treat the wrong hormone for the symptom, and the right one is one most women are never even told exists.
Low libido in perimenopause isn’t one problem with one fix. It splits into two: reduced desire, the wanting is gone, you don’t think about sex, you don’t initiate, and physical barriers, dryness, pain, lost sensation. Estrogen handles the second. Testosterone handles the first. Treat only the estrogen side when desire is the real complaint, and no dose and no amount of patience will fix it, because you’re treating a problem the patient doesn’t have.
Desire and physical comfort are different problems, they need different treatments
These two problems feel similar from the outside, “I don’t want sex anymore”, but they have different mechanisms and different treatments. Getting the distinction right is the entire decision.
| Problem | What It Feels Like | Primary Treatment |
| Reduced desire | No interest in initiating, fewer sexual thoughts, low spontaneous arousal | Testosterone |
| Physical discomfort | Dryness, pain during sex, reduced sensation | Estrogen (local or systemic) |
| Both | Both of the above | Both treatments |
The pattern that drives this table: most HRT prescriptions address estrogen and stop there. That’s appropriate if the problem is physical discomfort. But if the primary complaint is absent desire, the sexual thoughts are gone, not just the comfort, estrogen alone will rarely restore it, no matter the dose or how long you wait. You can have perfectly healthy vaginal tissue and still have no interest in sex, because the two are governed by different hormones.
This is the misread that wastes months: a woman says “my libido is gone,” gets estrogen, her physical symptoms improve, and her desire still doesn’t return, because desire was never an estrogen problem.
What estrogen does for sexual function
Estrogen’s role here is real but specific. It maintains the health of vaginal tissue, thickness, elasticity, blood flow, and drives lubrication and physical sensitivity. Restoring estrogen, whether through systemic HRT or local vaginal estrogen, reduces pain during sex and improves the physical arousal response.
Why this matters for libido, and the limit of why it matters. Pain and discomfort suppress desire over time through a straightforward feedback loop: sex that hurts becomes sex you stop wanting. Remove the pain, and for some women desire recovers on its own because the deterrent is gone. That’s a genuine, indirect libido benefit.
But here’s the boundary: estrogen does not directly drive sexual motivation. It removes a barrier to desire; it does not generate desire. If the discomfort was the only thing suppressing an otherwise intact sex drive, estrogen may be enough. If desire itself is gone, independent of any physical problem, estrogen is treating the wrong target, and the thing that drives motivation is testosterone.
(For full coverage of vaginal dryness and the genitourinary symptoms of menopause, see our companion article on HRT for Vaginal Dryness and GSM.)
Testosterone is the primary driver of sexual desire in women, and most women are never offered it
This is the part of the conversation that, for most women, simply never happens, and it’s the part that matters most when desire is the complaint.
How testosterone affects female libido
Testosterone is not just a male hormone. Women produce it in the ovaries and adrenal glands, and it acts on receptors in the brain that govern sexual motivation, fantasy, and the arousal response, the wanting, not just the mechanics. Levels decline gradually with age, and drop sharply after surgical menopause (removal of the ovaries), which removes a major production site abruptly rather than over years.
When testosterone is low, the result is a distinct symptom picture: reduced desire, fewer or absent spontaneous sexual thoughts, and a blunted ability to become aroused even with adequate stimulation. Critically, this is separate from the vaginal symptoms estrogen treats. A woman can have well-maintained tissue, comfortable sex, and still no drive, because the drive was the testosterone’s job.
What low testosterone looks like in women
The pattern that should specifically point toward the testosterone picture:
- Reduced or absent sexual desire
- Few or no spontaneous sexual thoughts
- Difficulty becoming aroused even with stimulation
- Reduced general energy and motivation, beyond the sexual context
These symptoms occurring in the presence of adequate estrogen, meaning the physical side has been addressed, comfort is fine, and desire is still missing. That combination is the clearest real-world signal that testosterone, not more estrogen, is the lever.
One honest caveat up front: there is no testosterone blood level that diagnoses this. The authoritative Global Consensus Position Statement on testosterone therapy for women is explicit that no cut-off circulating level distinguishes women with sexual dysfunction from those without. Testosterone is diagnosed from the symptom picture, with blood levels used as a baseline and a safety guardrail, not as the thing that proves deficiency. Any provider who rules testosterone in or out purely on a number is misapplying the evidence.
How testosterone is prescribed for women
Testosterone is prescribed off-label for women in the US, there is no FDA-approved testosterone product formulated specifically for female sexual dysfunction, even though the supporting evidence is substantial. In practice this means:
- Providers use government-approved male transdermal formulations, at much lower doses
- A typical female dose is roughly one-tenth of a male dose
- Gel or cream forms are standard; the Global Consensus Statement explicitly does not recommend oral testosterone, because it negatively affects cholesterol
- Blood levels are monitored to keep testosterone within the normal premenopausal female physiological range, the goal is restoration, never supraphysiologic (above-normal) levels
That last point is the safety architecture of the whole approach: you are replacing what’s missing to bring levels back into a woman’s normal range, not pushing them above it. Injectables, pellets, and compounded preparations are specifically excluded from the consensus recommendation because they tend to overshoot that range.
What “off-label” means for you, and how to ask for it
This word stops a lot of women, so it’s worth being precise. Off-label does not mean experimental, fringe, or unsafe. It means the manufacturer never pursued a specific regulatory approval for this use, often a commercial decision, not a scientific verdict.
Testosterone for low female desire is supported by multiple randomized controlled trials and a systematic review and meta-analysis of seven RCTs in 3,035 women, and it is endorsed by the International Society for the Study of Women’s Sexual Health and ten other major medical societies. This is one of the better-evidenced off-label uses in menopausal medicine.
A script that opens the conversation correctly: “I’ve read that testosterone is used off-label for low libido in women and is endorsed by international guidelines, can we discuss whether it’s appropriate for me, and check my testosterone and SHBG levels?” A provider who dismisses that out of hand, without discussion, is not current on the evidence, and that itself is useful information about whether you’re in the right place.
What to expect from testosterone therapy
Realistic expectations are part of the treatment, because the effect is meaningful but not dramatic, and the timeline is slow.
- Timeline: 3–6 months for meaningful improvement in desire. This is not a fast response, and judging it at week six guarantees a false negative.
- What improves: sexual thoughts, motivation to initiate, arousal response, and sexual satisfaction. Across the trial data, the averaged effect is roughly one additional satisfying sexual event per month over placebo, alongside improvements in desire and reduced sexual distress.
- What doesn’t change: relationship dynamics, stress-driven libido suppression, and, importantly, the trial evidence does not support testosterone improving mood, energy, or cognition, despite common claims. Women often report those benefits; randomized data doesn’t confirm them. Honest framing here protects you from disappointment and from overtreatment.
- Monitoring: blood levels at roughly 4–6 weeks, then every 6 months, plus monitoring for androgenic effects (acne, extra hair growth). These effects are usually mild at correct female dosing and reversible.
The trade-off: testosterone is the most effective tool for the desire half of the problem, with genuine RCT support, but the effect size is modest and slow, not a switch. It restores a meaningful degree of desire in appropriately selected women; it does not manufacture a libido that was never hormonally driven in the first place.
Psychological and relationship factors HRT won’t address
This is the boundary every honest version of this conversation has to include, because hormones can’t reach what isn’t hormonal.
HRT and testosterone treat the hormonal drivers of low libido. They do nothing for relationship conflict, chronic stress, depression, body-image concerns, or the effects of past trauma. The pattern that signals a non-hormonal driver: libido was already low before perimenopause, or desire is present but directed away from a specific partner rather than globally absent. In those cases, hormonal treatment alone is unlikely to resolve anything, because the cause was never the hormones.
This isn’t a reason to skip hormonal evaluation, both can be true at once, and frequently are. But a sex therapist or psychologist with sexual-health expertise belongs alongside hormonal treatment when these factors are present. A provider who treats libido as a purely endocrine problem, with no acknowledgment of the psychological and relational layer, is giving you half a model.
A complete evaluation for low libido, what it should include
Most “HRT didn’t help my libido” stories trace back to an incomplete evaluation, specifically, one that looked at estrogen and nothing else. A complete workup checks every lever that independently suppresses desire.
| Assessment Component | Purpose |
| Total and free testosterone | Identify the desire driver; establish baseline for monitoring |
| Estradiol level | Rule out estrogen deficiency as a physical barrier |
| SHBG (sex hormone-binding globulin) | High SHBG binds testosterone and reduces what’s biologically available |
| Thyroid function (TSH, free T4) | Hypothyroidism suppresses libido independently of sex hormones |
| Medication review | SSRIs, beta-blockers, and oral contraceptives all suppress libido |
Two rows deserve emphasis. SHBG is the most overlooked: it’s a protein that binds testosterone in the blood, and when it’s high, which oral estrogen and oral contraceptives both cause, your total testosterone can look adequate while the free, usable fraction is depleted.
Measuring testosterone without SHBG can completely miss this. And the medication review catches the cause hiding in plain sight: SSRleeI antidepressants are a frequent, reversible contributor, and no amount of hormone therapy overrides an ongoing pharmacological suppressor.
The rule: if your provider addresses only estrogen without reviewing testosterone, free testosterone, and SHBG, the evaluation is incomplete, and an incomplete evaluation is the single best predictor of a treatment that “doesn’t work.”
What to do next
If you take one thing from this: if you’re already on HRT and your libido hasn’t improved, the answer is almost certainly in the testosterone picture, either it was never assessed, or SHBG is masking a deficiency. That’s the first place to look, not a higher estrogen dose.
Two questions to bring to your appointment:
- “What are my total testosterone, free testosterone, and SHBG levels?” If these were never measured, your low-libido workup was incomplete by definition, this is the missing data.
- “If testosterone is low or low-normal with high SHBG, can we discuss off-label testosterone therapy?” Phrasing it this way signals you understand the evidence and the SHBG nuance, and it makes a dismissive non-answer easy to recognize.
Low libido done well is a process of separating the two problems, treating each with the hormone that actually governs it, ruling out the non-hormonal suppressors, and giving testosterone the 3–6 months it needs to work. Done poorly, it’s an estrogen prescription and a shrug when desire doesn’t return, which is the experience far too many women are handed.
If you want the version that actually evaluates both halves, testosterone and free testosterone and SHBG, not just estrogen, with realistic timelines and physiological-range monitoring, that’s the model TRTMD is built around. A consultation maps the full hormonal picture, including the testosterone and SHBG data most evaluations skip, before anything is prescribed. The goal isn’t to refill estrogen and hope, it’s to identify which of the two problems you actually have, and treat that one.
